Systemic Lupus Erythematosus (Libman-Sacks Disease)

Subscribe to Selected New Research on Systemic Lupus Erythematosus

12124 relevant articles (295 outcomes, 938 trials/studies) found for this Disease

Description: A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.

Also Known As:

Libman-Sacks Disease; Lupus Erythematosus, Systemic; Disease, Libman-Sacks; Libman Sacks Disease; Lupus Erythematosus Disseminatus

Relationship Network

Disease Context: Research Results

Skin and Connective Tissue Diseases

Connective Tissue Diseases: 1633

Systemic Lupus Erythematosus: 12124

Lupus Nephritis: 1995

Central Nervous System Lupus Vasculitis: 68

Immune System Diseases: 1237

Autoimmune Diseases: 11588

Systemic Lupus Erythematosus: 12124

Lupus Nephritis: 1995

Central Nervous System Lupus Vasculitis: 68

Related Diseases

1.	Rheumatoid Arthritis
2.	Autoimmune Diseases (Autoimmune Disease)
3.	Syndrome
4.	Vasculitis (Vasculitides)
5.	Glomerulonephritis

Experts

1.	Isenberg, D A: 21 articles (10/2008 - 04/2000)
2.	Tsokos, George C: 18 articles (02/2007 - 01/2002)
3.	Petri, M: 14 articles (04/2008 - 05/2000)
4.	Petri, Michelle: 13 articles (10/2008 - 06/2002)
5.	Manzi, Susan: 13 articles (09/2008 - 04/2004)
6.	Nasonov, E L: 12 articles (01/2008 - 01/2000)
7.	Font, J: 11 articles (03/2008 - 01/2000)
8.	Khamashta, M A: 11 articles (05/2005 - 05/2000)
9.	Harley, John B: 10 articles (08/2008 - 10/2002)
10.	Crow, Mary K: 10 articles (08/2008 - 09/2003)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Systemic Lupus Erythematosus:

1.	Cyclophosphamide (Cytoxan)FDA Link 04/01/2006 - "Intermittent intravenous cyclophosphamide pulse therapy (IVCY) has been reported to be effective for the treatment of refractory systemic lupus erythematosus (SLE)" 10/15/2001 - "PURPOSE: Cyclophosphamide-induced ovarian failure has been reported to be protective against flares of systemic lupus erythematosus (SLE)" 10/01/2006 - "METHODS: Patients (n = 7) with systemic lupus erythematosus (SLE) and proliferative nephropathy confirmed by renal biopsy, in whom disease remission was induced with intravenous cyclophosphamide, received MMF (2 x 500 mg daily) for 3 months" 02/01/1998 - "To our knowledge this is the first case of pulse i.v. cyclophosphamide therapy in infantile systemic lupus erythematosus resulting in long-term remission." 02/01/1998 - "Remission of infantile systemic lupus erythematosus with intravenous cyclophosphamide." Order ALL the reference details at left...
2.	Antigen-Antibody Complex (Immune Complex)IBA 12/01/2005 - "Hypocomplementaemia and low expression of CR1 on erythrocytes (E) of patients with systemic lupus erythematosus (SLE) are associated with defective clearance of circulating immune complexes (IC) and so they may have pathogenic significance" 12/01/2000 - "Fcgamma receptor polymorphisms in systemic lupus erythematosus: association with disease and in vivo clearance of immune complexes." 01/01/2003 - "Studies of gene-targeted mice lacking specific FcgammaR have demonstrated that animals lacking activator FcgammaR on circulating leukocytes were protected from immune complex induced glomerular injury, both in models of systemic lupus erythematosus (SLE) and anti-glomerular basement membrane antibody disease" 11/01/2002 - "OBJECTIVE: Studies of an Icelandic cohort showed that susceptibility to systemic lupus erythematosus (SLE) in individuals with C4A deficiency was increased only in the presence of increased concentrations of immune complexes" 01/01/2001 - "A number of mouse models have been utilized to study the pathophysiology of immune complex (IC) disease, and the hallmark IC disease systemic lupus erythematosus (SLE)" Order ALL the reference details at left...
3.	DNA (Deoxyribonucleic Acid)IBA 10/01/1992 - "The rate of clearance of extracellular plasma DNA in man has important implications for pathogenetic mechanisms in systemic lupus erythematosus (SLE), as well as for certain other clinical states" 11/01/2004 - "BACKGROUND: Previous studies have suggested that interrupted clearance of nuclear DNA-protein complexes after cell death might initiate and propagate systemic lupus erythematosus (SLE)" 09/01/2008 - "A peptide, designated human CDR1 (hCDR1), that is based on the CDR1 of an anti-DNA Ab ameliorates systemic lupus erythematosus (SLE) in murine models via the induction of CD4(+)CD25(+) regulatory T cells (Tregs)" 11/01/2006 - "A peptide (hCDR1) based on the complementarity determining region-1 of an anti-DNA antibody ameliorates systemic lupus erythematosus (SLE) in induced and spontaneous lupus models" 01/30/2001 - "The mechanism by which a peptide based on complementarity-determining region-1 of a pathogenic anti-DNA auto-Ab ameliorates experimental systemic lupus erythematosus." Order ALL the reference details at left...
4.	Immunoglobulin G (IgG)IBA 02/01/2001 - "A bispecific dsDNAxmonoclonal antibody construct for clearance of anti-dsDNA IgG in systemic lupus erythematosus." 04/01/1988 - "Abnormal clearance of soluble aggregates of human immunoglobulin G in patients with systemic lupus erythematosus." 02/01/1984 - "Defective clearance of IgG-sensitized particles has been documented in systemic lupus erythematosus (SLE)" 12/17/1982 - "Some variation in the degree of coating of cells from patients with systemic lupus erythematosus was found although the differences were insufficient to account for the reported reduction in the clearance of IgG-coated cells in patients with this disease" 07/01/1976 - "Inhibitory factors were present in 7S and heavier fractions containing IgG. Five systemic lupus erythematosus patients were studied serially to determine if improvement in clinical status could be correlated with a decrease in serum inhibitory factors as studied by inhibition of normal antibody-dependent cell-mediated cytotoxicity" Order ALL the reference details at left...
5.	AntibodiesIBA 09/01/1994 - "Anti-Id antibodies to O-81-Id occurred spontaneously during the remission of systemic lupus erythematosus (SLE) but rarely during an acute episode" 06/01/2007 - "This study was undertaken to investigate whether polyclonal anti-dsDNA antibodies promote the local secretion of lipocalin-2 in the kidneys of patients with systemic lupus erythematosus (SLE), and whether urinary lipocalin-2 represents a marker of kidney involvement in SLE" 06/01/2005 - "The aim of this study was to investigate the clinical significance of antinucleosome antibodies in Tunisian systemic lupus erythematosus (SLE) patients" 06/01/2004 - "The study of the participation of basement membrane zone antibodies in the formation of the lupus band in systemic lupus erythematosus." 05/01/2004 - "Two well-designed studies of anti-CD154 antibodies in systemic lupus erythematosus were reported" Order ALL the reference details at left...
6.	rituximab (Mabthera)FDA Link 08/01/2004 - "B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab." 04/01/2007 - "Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system." 05/01/2006 - "OBJECTIVE: To describe the safety and efficacy of rituximab in the treatment of childhood-onset systemic lupus erythematosus (SLE)" 09/01/2007 - "This study was undertaken to determine the magnitude, duration, and cause of these defects in rituximab-treated systemic lupus erythematosus (SLE) patients" 01/01/2007 - "A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus." Order ALL the reference details at left...
7.	Prednisone (Sone)FDA LinkGeneric 07/01/2000 - "METHODS: A double blind placebo controlled study to evaluate 81 premenopausal women with systemic lupus erythematosus (SLE), aged 31.1 +/- 6 years, taking chronic steroid therapy, with a mean cumulative prednisone dose of 28 +/- 16.2 g" 02/01/1969 - "Bone biopsy studies in systemic lupus erythematosus treated with encortone]" 03/01/2006 - "Systemic lupus erythematosus was diagnosed and prednisone therapy was introduced" 10/01/2005 - "A woman with chronic systemic lupus erythematosus (SLE) was treated with prednisone, and developed an acute febrile neuroinfection" 04/01/2005 - "CASE REPORT: A 43-year-old female with systemic lupus erythematosus under treatment with immunosuppressive drugs and prednisone was submitted to colonoscopy because of a change in bowel habit" Order ALL the reference details at left...
8.	AutoantibodiesIBA 01/01/1988 - "Also no false-positive results were obtained with 20 sera from systemic lupus erythematosus patients which had high titers of cross-reactive autoantibodies" 08/01/2004 - "Reduction of pathological autoantibodies may be useful in the treatment of systemic lupus erythematosus (SLE)" 08/01/2008 - "In the present study, we investigated the association between high-sensitivity CRP (hsCRP) and systemic lupus erythematosus (SLE) manifestations, autoantibodies, and organ damage" 04/01/2008 - "OBJECTIVE: To study EKG PR interval in adult systemic lupus erythematosus (SLE) patients with anti-Ro anti-La and anti-RNP autoantibodies" 01/01/2006 - "The aim of this study was to determine the association between lupus autoantibodies and the clinical manifestations and outcome in a cohort of Puerto Ricans patients with systemic lupus erythematosus (SLE)" Order ALL the reference details at left...
9.	Dehydroepiandrosterone (DHEA)IBA 01/01/1999 - "OBJECTIVE: To determine if dehydroepiandrosterone (DHEA) is beneficial in severe systemic lupus erythematosus (SLE)" 02/01/1998 - "OBJECTIVE: To determine whether longterm therapy (up to 1 year) with the weakly androgenic adrenal steroid dehydroepiandrosterone (DHEA) is feasible and beneficial in patients with mild to moderate systemic lupus erythematosus (SLE)" 12/01/1995 - "OBJECTIVE: To determine if dehydroepiandrosterone (DHEA) is beneficial in the treatment of systemic lupus erythematosus (SLE)" 02/01/2003 - "Treatment with dehydroepiandrosterone was effective in randomized controlled trials in patients with systemic lupus erythematosus" 11/01/2005 - "The objective of this study was to evaluate the efficacy of low dose dehydroepiandrosterone (DHEA) on health-related quality of life (HRQOL) in glucocorticoid treated female patients with systemic lupus erythematosus (SLE)" Order ALL the reference details at left...
10.	Adrenal Cortex Hormones (Corticosteroids)IBA 11/01/2006 - "The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial." 11/01/2003 - "OBJECTIVE: To study bone mineral density (BMD) in premenopausal women with systemic lupus erythematosus (SLE) and to evaluate the influence of disease activity and use of corticosteroids" 10/01/2002 - "Cardiac consequences of the systemic lupus erythematosus therapy with corticosteroids morphological study." 08/01/1995 - "The aim of our study was to assess bone mineral density (BMD) in pre-menopausal women with systemic lupus erythematosus (SLE) and the influence of disease activity and use of corticosteroids" 09/01/1994 - "This study was designed to assess the effects of corticosteroids on select aspects of nervous system functioning, specifically, cognition and mood, as well as disease-related symptoms in individual patients with mild systemic lupus erythematosus (SLE) and mild neuropsychiatric (NP) symptoms" Order ALL the reference details at left...

Therapies and Procedures

1.	Plasmapheresis 01/01/1978 - "Direct attempts to alter the levels of complexes by plasmapheresis, an effective treatment for acute exacerbations of systemic lupus erythematosus (SLE), have been disappointing in rheumatoid disease" 11/01/1986 - "Treatment with successive courses of plasmapheresis produced clinical and electrophysiologic improvement in her ELS, without affecting her systemic lupus erythematosus" 02/01/2002 - "To examine the possible effect of plasmapheresis on the ratio of Th1/Th2 type cytokine-secreting cells we recruited eight patients with active systemic lupus erythematosus into the present study" 10/01/1991 - "A group of clinics cooperating as the Lupus Plasmapheresis Study Group (LPSG) is starting an international multicenter study of the treatment of severe systemic lupus erythematosus" 01/01/1988 - "Use of plasmapheresis in therapy of systemic lupus erythematosus: a controlled study]" Order ALL the reference details at left...
2.	Transplants (Transplant) 08/01/2003 - "At Northwestern University, a phase I/II trial of hematopoietic stem cell transplant (HSCT) for systemic lupus erythematosus (SLE) has shown promising results" 11/01/2002 - "The use of anti-CD20 monoclonal antibody for in vivo B cells depletion and early trials of autologous peripheral stem cell transplants represent additional immunomodulatory treatment modalities for systemic lupus erythematosus patients" 09/01/2008 - "Pauci-immune and immune glomerular lesions in kidney transplants for systemic lupus erythematosus." 07/01/2008 - "Twenty-six patients with systemic lupus erythematosus (SLE) subjected to 26 kidney transplants were studied" 10/15/2007 - "Chronic graft-vs-host (cGVH) disease is a well-characterized systemic lupus erythematosus (SLE) model" Order ALL the reference details at left...
3.	Plasma Exchange 04/01/2007 - "Efficacy of plasma exchange in patients with systemic lupus erythematosus has not been supported by the results of the first non-controlled and retrospective studies" 01/01/1985 - "The case reported concerns a child presenting with systemic lupus erythematosus (SLE) with acute neurological symptoms who improved after plasma exchanges" 01/01/1983 - "The effects of intensive plasma exchange on the serological and clinical manifestations of mildly active systemic lupus erythematosus were evaluated in a controlled, double-blind trial" 01/01/1983 - "Randomised trial of plasma exchange in mild systemic lupus erythematosus." 04/01/2007 - "Plasma exchange for systemic lupus erythematosus." Order ALL the reference details at left...
4.	Hematopoietic Stem Cell Transplantation 11/01/2002 - "OBJECTIVE: To determine the safety and long-term efficacy of immune ablation and autologous hematopoietic stem cell transplantation (HSCT) in severe systemic lupus erythematosus (SLE)" 08/01/2003 - "Development of a phase III trial of hematopoietic stem cell transplantation for systemic lupus erythematosus." 09/01/2007 - "The first autologous hematopoietic stem cell transplantation in Europe for a patient with severe refractory systemic lupus erythematosus (SLE) was performed in Genoa in 1996" 06/01/2006 - "Granulocytic invasion of the central nervous system after hematopoietic stem cell transplantation for systemic lupus erythematosus." 02/01/2006 - "Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus." Order ALL the reference details at left...
5.	Transplantation (Transplant Recipients) 03/15/2003 - "The purpose of this study was to determine the incidence of RLN in a large cohort of renal transplant recipients with systemic lupus erythematosus (SLE)" 08/15/2007 - "Patients with severe systemic lupus erythematosus (SLE) refractory to conventional treatment are candidates for autologous hematopoietic stem cell (HSC) transplantation if the intent is to reset the immunologic clock" 04/01/2004 - "Mandibular augmentation with vascularized fibula transplantation in a patient with systemic lupus erythematosus." 11/01/2002 - "Transplantation of purified CD34+ stem cells from autologous peripheral blood for treatment of systemic lupus erythematosus]" 01/01/1999 - "Control of severe systemic lupus erythematosus after high-dose immunusuppressive therapy and transplantation of CD34+ purified autologous stem cells from peripheral blood." Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Systemic Lupus Erythematosus

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 295 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>